Neoadjuvant atezolizumab with chemotherapy followed by adjuvant atezolizumab for treating triple-negative breast cancer

Neoadjuvant atezolizumab in combination with chemotherapy followed by adjuvant atezolizumab is currently in clinical development for patients with triple-negative breast cancer (TNBC). TNBC develops in about 1 in 5 women with breast cancer and is one of the most difficult forms of breast cancer to treat due to the lack of receptors that are common targets for treatment in breast cancer. TNBC is often more aggressive compared to other types of breast cancer and there are a lack of safe treatments for this population group.